Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ (Deficit) Equity - USD ($) $ in Thousands	Total	Series 1 Preferred	Common Stock	Treasury Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Series 1 Preferred	Series 1 Preferred Series 1 Preferred
Preferred stock, beginning balance (in shares) at Dec. 31, 2021									452,000
Preferred stock, beginning balance at Dec. 31, 2021									$ 18,036
Preferred stock, ending balance (in shares) at Mar. 31, 2022									452,000
Preferred stock, ending balance at Mar. 31, 2022									$ 18,036
Balance, beginning of period (in shares) at Dec. 31, 2021			8,497,025	67,746
Balance, beginning of period at Dec. 31, 2021	$ 24,395		$ 85	$ (5,056)	$ 580,156	$ (550,452)	$ (338)
Increase (Decrease) in Stockholders' Equity
Share-based compensation	599				599
Issuance of common stock upon vesting of restricted stock units (in shares)			122,928
Issuance of common stock upon vesting of restricted stock units	0		$ 1		(1)
Issuance of common stock upon exercise of pre-funded warrants (in shares)			56,950
Issuance of common stock upon exercise of pre-funded warrants	0		$ 1		(1)
Comprehensive loss	(7,565)					(7,562)	(3)
Balance, end of period (in shares) at Mar. 31, 2022			8,676,903	67,746
Balance, end of period at Mar. 31, 2022	17,429		$ 87	$ (5,056)	580,753	(558,014)	(341)
Preferred stock, beginning balance (in shares) at Dec. 31, 2022									452,000
Preferred stock, beginning balance at Dec. 31, 2022	18,036								$ 18,036
Preferred stock, ending balance (in shares) at Mar. 31, 2023									452,000
Preferred stock, ending balance at Mar. 31, 2023	$ 22,564							$ 22,600	$ 22,564
Balance, beginning of period (in shares) at Dec. 31, 2022	8,614,701		8,682,447	67,746
Balance, beginning of period at Dec. 31, 2022	$ 2,015		$ 87	$ (5,056)	582,763	(575,425)	(354)
Increase (Decrease) in Stockholders' Equity
Share-based compensation	559				559
Issuance of common stock upon vesting of restricted stock units (in shares)			1,597
Issuance of common stock upon vesting of restricted stock units	0
Issuance of common stock upon exercise of pre-funded warrants (in shares)			430,000
Issuance of common stock upon exercise of pre-funded warrants	0		$ 4		(4)
Accretion of Series 1 preferred stock redemption	(4,528)	$ 4,528			(4,528)
Comprehensive loss	$ (8,066)					(8,066)	0
Balance, end of period (in shares) at Mar. 31, 2023	9,046,298		9,114,044	67,746
Balance, end of period at Mar. 31, 2023	$ (10,020)		$ 91	$ (5,056)	$ 578,790	$ (583,491)	$ (354)